Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid Nebulization vs IV for Hemoptysis
NCT07212452Phase 3
Key facts
- Status
- Completed
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Countries
- 1
- Sponsor
- University of Health Sciences Lahore
- Modality
- Small Molecules
- Drugs
- tranexamic acid
- Conditions
- hemoptysis
01
Overview
Phase 3, randomised trial of tranexamic acid in hemoptysis (2 arms), sponsored by University of Health Sciences Lahore. Primary endpoint: Time to control hemoptysis at 48 hours. Started Aug 2025; status: completed.
02
Design
2 arms- Study design
- Randomized
IV Tranexamic Acid
Tranexamic acid given via IV route
Nebulized Tranexamic Acid
Tranexamic acid given via nebulization
03
Who it enrols
Patients aged 12-80 with mild to moderate hemoptysis (<600ml/24h) due to infective or malignant pathology, excluding those on antiplatelet therapy/aspirin, with penetrating lung injury, or history of asthma.
04
Endpoints
Primary
Time to control hemoptysis
Secondary
Recurrence time
Reduction in amount of blood in sputum
Beyond the preview
Go deeper on NCT07212452.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07212452.